Lantern Earnings Wednesday, November 18, 2026 -0.30 Negative

Lantern Reports Q3 2026 Results, Closes $4M Offering

Lantern Pharma achieved mixed operational results, with R&D costs decreasing by 36% while reporting a net loss. The company announced the engagement of the first clinical site for a TNBC trial and closed an approximately $4.0 million registered direct offering.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed